Acrivon Therapeutics, Inc.
Moat Score — Acrivon Therapeutics, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Acrivon's proprietary AP3 functional proteomics biomarker platform is protected by patents and represents a scientifically differentiated approach to patient selection that is distinct from the genomic-only biomarker strategies used by most DDR-pathway competitors. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a pre-commercial clinical-stage biotech, Acrivon has no manufacturing or commercial scale advantage versus larger oncology competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products, Acrivon has no realized pricing power today; future pricing would depend on the clinical differentiation ACR-368 and AP3 demonstrate relative to competing DDR-pathway therapies. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Oncology therapeutics and companion diagnostic biomarker platforms do not exhibit network effects tied to user count. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no commercialized product yet, there are no entrenched prescribers or diagnostic workflows creating switching costs for Acrivon's platform today. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The DDR-pathway oncology space includes several well-funded competitors pursuing related targets, so efficient scale offers limited protection for a smaller platform company like Acrivon. |